On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients

Por de Boer, Nanne KH, Derijks, Luc JJ, Gilissen, Lennard PL, Hommes, Daniel W, Engels, Leopold GJB, de Boer, Sybrand Y, den Hartog, Gijsbertus, Hooymans, Piet M, Mäkelburg, Anja BU, Westerveld, Barend D, Naber, Anton HJ, Mulder, Chris JJ, de Jong, Dirk J
Publicado no World J Gastroenterol (2005)

More Dose-dependent Side Effects with Mercaptopurine over Azathioprine in IBD Treatment Due to Relatively Higher Dosing

Por Broekman, Mark M. T. J., Coenen, Marieke J. H., van Marrewijk, Corine J., Wanten, Geert J. A., Wong, Dennis R., Verbeek, Andre L. M., Klungel, Olaf H., Hooymans, Piet M., Guchelaar, Henk-Jan, Scheffer, Hans, Derijks, Luc J. J., de Jong, Dirk J.
Publicado no Inflamm Bowel Dis (2017)

Patients’ beliefs about medicine are associated with early thiopurine discontinuation in patients with inflammatory bowel diseases

Por Broekman, Mark M.T.J., Coenen, Marieke J.H., Wanten, Geert J., van Marrewijk, Corine J., Kievit, Wietske, Klungel, Olaf H., Verbeek, André L.M., Wong, Dennis R., Hooymans, Piet M., Guchelaar, Henk-Jan, Scheffer, Hans, Derijks, Luc J.J., Bouvy, Marcel L., de Jong, Dirk J.
Publicado no Eur J Gastroenterol Hepatol (2018)